Most material SEC filings — July 22, 2026

China Pharma Holdings priced a registered direct offering on July 22, 2026, selling 2.5 million shares at $2.00 per share for $5 million gross proceeds. The offering was conducted under an effective Form S-3 registration statement (File No. 333-276481, effective February 14, 2024). FT Global Capital, Inc. served as exclusive placement agent, earning a 7% placement fee ($350,000). Net proceeds are designated for working capital and general corporate purposes.

Domo, Inc. has entered into an Asset Purchase Agreement dated July 22, 2026, to sell substantially all of its business assets and transferred subsidiaries to Progress Software Corporation. The agreement includes purchase price adjustments based on closing cash and indebtedness, with Domo's board unanimously approving the transaction and majority stockholders executing a support agreement. The buyer will assume specified liabilities while Domo retains excluded assets, employee liabilities, and certain tax attributes.

Intersnack Group GmbH Co. KG (Parent) agreed to acquire Utz Brands, Inc. via merger with Merger Sub for $14.25 per Class A Common Share in cash (Merger Consideration). The agreement, dated July 20, 2026, also includes a $44 million Tax Receivable Agreement (TRA) termination payment to Continuing Stockholders (Series U and Series R) and a Recapitalization whereby Continuing Stockholders will own 50% of Company LLC post-Closing. The Special Committee and Company Board unanimously approved the transaction as fair and in the best interests of unaffiliated stockholders.

Axe Compute announced $1.3B in new customer contracts (exceeding its $1B midyear 2026 target) across U.S. and Europe under its Build program, structured as five-year commitments with upfront prepayments. Revenue deployment begins late Q4 2026 with prepayments in Q3 2026, projected to boost ARR to over $384M upon deployment. CEO stated additional $2B in contracts possible by year-end.

Purple Innovation, Inc. filed an 8-K on July 22, 2026 reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing does not disclose the specific listing standard violated, the exchange involved, the timeline to cure, or remediation plans. No financial impacts, counterparties, or dollar amounts are detailed in the document header.

Avanos Medical stockholders voted on July 22, 2026 to approve acquisition by American Industrial Partners (AIP) affiliates at $25.00 per share in cash. Approximately 99.75% of shares voted at the special meeting approved the transaction, representing 74.96% of total outstanding shares as of June 18, 2026 (record date). All regulatory approvals received; transaction expected to close by July 27, 2026.

Northfield Bancorp, Inc. (market cap ~$437.7M) filed an 8-K on July 22, 2026 reporting as of July 20, 2026 covering completion of an acquisition/disposition (Item 2.01), notice of delisting or listing standard failure (Item 3.01), material modifications to security holder rights (Item 3.03), change in control (Item 5.01), director/officer departures and elections (Item 5.02), and potential charter/bylaw amendments (Item 5.03). The filing document itself does not contain the specific dollar amounts, counterparty names, share counts, or detailed transaction terms—only the item headings are disclosed in this index page. No concrete financial metrics or deal structure are provided in the accessible text.

Mentari Therapeutics, Inc. announced a $200 million private placement (Amendment No. 1 to Securities Purchase Agreement dated July 22, 2026) consisting of common stock and pre-funded warrants from investors including Fairmount, ADAR1 Capital Management, Venrock Healthcare, Sirenia Capital, Janus Henderson, Blackstone, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, and BB Biotech. The placement is expected to close concurrently with Mentari's previously announced $290 million private placement and immediately before completion of its merger with InMed Pharmaceuticals (Nasdaq: INM). Combined, these financings will extend Mentari's cash runway to 2029 and fund Phase 2a readouts for migraine prevention pipeline programs MT-001 and MT-002. Post-merger, estimated total shares outstanding on an as-converted/as-exercised basis will be approximately 601.2 million.

SunPower Inc. filed Form 8-K on July 22, 2026, disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing indicates the company has received a delisting notice, though the specific exchange, listing standards violated, and remediation timeline are not detailed in the header information provided.

On July 22, 2026, Penske Corporation and Mitsui & Co., Ltd.—which collectively own 72.6% of PAG—submitted an unsolicited, non-binding proposal to acquire all remaining shares at $210 per share in cash, implying ~$13.8B equity value and a 19.3% premium to 60-day VWAP. The proposal is subject to Board approval and negotiation of definitive documents, with no financing conditions; the special committee of independent directors will evaluate and may reject it. The acquirers commit not to divest their current stake and not to vote for alternative transactions, positioning themselves as long-term investors post-deal.

Repligen Corporation agreed to acquire BioLife Solutions Inc. in an all-stock and cash transaction dated July 21, 2026. BioLife shareholders will receive 0.1442 shares of Repligen common stock plus $11.25 cash per share. The transaction values BioLife at approximately $845M (company's public market value). Both boards unanimously approved; deal is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code and subject to BioLife shareholder approval and regulatory clearances including HSR Act compliance.

DarioHealth Corp. priced a registered direct offering of 3,454,559 shares at $6.80/share (with pre-funded warrants available), generating ~$23.5M gross proceeds. The offering closed on or about July 23, 2026. A.G.P./Alliance Global Partners acted as sole placement agent; existing institutional investors and new investors participated. Net proceeds to be used for working capital, investments, acquisitions, and general corporate purposes.

CID Holdco issued 400,000 shares of Series AA Preferred Stock and 800,000 shares of Series B Preferred Stock for $6,000,000 total ($2M Series AA at $5/share; $4M Series B at $5/share) to Alumni Capital LP (lead investor) and Veridis Capital LLC. Series AA converts to Common Stock at $1.00/share; Series B converts to Series AAA at $5.00/share which then converts to Common Stock at $0.0901/share. Investors gain board seat (15% holder) and majority control (Series B trigger event), plus registration and participation rights.

As of July 22, 2026, Alzamend Neuro had 4,791,525 shares of common stock outstanding (par value $0.0001) with 300M shares authorized. The company's independent auditor (Haskell White LLP) issued a going concern opinion, expressing substantial doubt about the company's ability to continue operations. Capital structure includes 10M authorized preferred shares.

On July 21, 2026, NOVAGOLD entered into definitive agreements to acquire Paulson Advisers' 40% ownership interest in Donlin Gold for an all-share transaction. NOVAGOLD (currently 60% owner) will acquire Paulson's stake, resulting in 100% ownership. Current NOVAGOLD shareholders will own ~65% of the new U.S.-domiciled parent (NovaGold Corporation); Paulson will own ~40% economic interest (capped at 19.99% voting) on a fully diluted basis. The transaction, valued at implied ~$4.2B equity value based on NOVAGOLD's $5.63/share closing price on July 21, 2026, is expected to close Q4 2026 subject to 66⅔% shareholder approval, court approval, and regulatory clearances. Paulson and certain NOVAGOLD insiders holding ~28% of shares have committed voting support.

On July 17, 2026, SunPower Inc. settled three OTC equity prepaid forward transactions with: (1) Meteora Capital funds—$6.44M settlement amount, 10.15M maturity shares issued on 3.22M original shares; (2) Polar Multi-Strategy Master Fund—$4.18M settlement amount, 6.59M maturity shares issued on 2.09M original shares; (3) Diametric True Alpha funds—$995K settlement amount, 1.16M settlement shares issued on 498K original shares plus monthly $50K amortization payments through full settlement. Total share issuance: ~17.9M shares. All agreements include registration statement obligations (Form S-1 within 5 business days, effective by Aug 14, 2026) with 1.0% monthly registration default penalties if missed.

Evolution Metals (EMAT, $7.1M market cap) received its first 5 metric ton delivery of NdPr metals from SRE Vietnam (via Senri Trading/Tokai Trading) on July 22, 2026. This feedstock enables EMAT to produce DFARS 252.225-7052-compliant rare earth magnets for U.S. defense systems ahead of the January 1, 2027 deadline. EMAT claims to be the only known commercial-scale producer of defense-compliant magnets and expects to scale to ~10,000 metric tons annual capacity by November 2026 using 13 ULVAC machines; no dollar amount disclosed for this shipment or supply agreement.

Medalist Diversified signed two purchase agreements on 21 July 2026 to acquire net-leased commercial properties from NPH Ventures LLC: (1) Aubrey, Texas property (Denton County) for $5,494,444, leased to Caliber Bodyworks with 30-year lease; (2) Cleburne, Texas property (Johnson County) for $5,648,000, same tenant with 20-year lease and defined rent escalations ($330k–$484k annually). Combined purchase price $11,142,444; combined earnest money deposits $227,000. Both deals are structured identically with 30-day inspection periods, 60-day closing timelines, and one extension option each.

On July 2, 2026, Iridium closed acquisition of Aireon LLC for ~$366.7M ($183.4M cash at close, $183.4M seller note due 1 year, 0% interest). Deal expected to add $100M+ annual service revenue and $30M OEBITDA. Separately, on June 28, 2026, Rocket Lab agreed to acquire Iridium (expected mid-2027 close, subject to stockholder approval). Q2 2026: revenue $225.2M (+4% YoY), net income $9.7M ($0.09/share, down from $22.0M/$0.20 in Q2 2025 due to transaction costs), OEBITDA $119.1M (-2% YoY), subscribers 2.627M (+6% YoY).

Summit announced updated overall survival (OS) data from the global Phase III HARMONi trial of ivonescimab plus chemotherapy versus placebo plus chemotherapy in EGFR-mutated NSCLC patients previously treated with third-generation EGFR TKIs. The June 2026 data cut-off showed hazard ratio of 0.76 (95% CI: 0.62–0.98) in the full intention-to-treat population and western patient subgroup, with median OS of 16.8 months (ivonescimab + chemo) versus 14.0 months (placebo + chemo); western patient median follow-up improved from 9.2 months (April 2025 primary analysis) to 23.2 months. The BLA with FDA has a PDUFA goal date of November 14, 2026.

Monopar announced on July 22, 2026, that it has initiated a rolling New Drug Application (NDA) submission to the FDA for ALXN1840 (tiomolibdate choline), a first-in-class treatment for Wilson disease. The company has already submitted completed sections of the NDA and received FDA authorization for rolling review. ALXN1840 has Fast Track, Orphan Drug, and Rare Pediatric Disease (RPD) designations, with the RPD designation potentially entitling the company to a pediatric Priority Review Voucher (PRV) upon approval. The pivotal Phase 3 trial met its primary endpoint, demonstrating superior copper mobilization versus standard of care, with favorable safety across 266 patients.

Apex Treasury Corporation (Cayman Islands SPAC) agreed to merge with TECfusions, Inc. (Florida data center company) via a business combination. TECfusions shareholders receive Domesticated Purchaser Common Stock at an Exchange Ratio to be determined. The merger involves domestication of Apex to Delaware, issuance of PIPE investment securities, shareholder redemptions, and various regulatory filings. Closing expected after shareholder approvals and regulatory clearances, with outside date implications tied to financial statement delivery.

Kairos Pharma (market cap ~$6.9M) entered an Investigator-Initiated Research (IIR) agreement with Bayer HealthCare Pharmaceuticals dated July 16, 2026, to conduct a preclinical study combining Bayer's XOFIGO (radium-223 dichloride) with Kairos's lead candidate ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer with bone metastasis. Study runs June–December 2026 with report due January 2027. Kairos retains ownership of study results but grants Bayer a non-exclusive, perpetual, royalty-free license to all data; Bayer holds a 3-month exclusive option to negotiate a license to study data and patent rights. No financial terms disclosed; agreement is standard IIR format with typical liability caps ($1,000/year) and confidentiality provisions (10-year post-term). Principal Investigator: Neil Bhowmick, PhD (Kairos CSO).

Kensington Capital Acquisition Corp. VI (SPAC, ~$232.7M assets) signed definitive merger agreement with Nth Cycle Inc., a Delaware corporation, dated July 21, 2026. Deal structure: two-step merger with Nth Cycle surviving as LLC subsidiary of domesticated Purchaser. Consideration includes stock exchange (ratio TBD based on fully-diluted shares), contingent earnout of up to 20M shares (10M at $15 stock price achievement, 10M upon 6,000 tpy refinery completion), both capped at 7-year post-close window. Concurrent PIPE investment of up to $100M minimum. No specific dollar valuation stated; exchange ratio and earnout triggers define economics.

Elong Power (ELPW), a $27.7M-asset Cayman Islands energy storage company, filed an F-1 to register up to 40M units ($0.25/unit assumed price = $10M gross) plus 40M pre-funded units, each bundled with warrants exercisable at $0.25 (100% of offering price) for 3 years. Maxim Group is placement agent (7% fee, best efforts). Net proceeds ~$9M estimated. Company has conducted two 1-for-16 and 1-for-80 share consolidations in past 7 months; stock trades below $1.00; Nasdaq delisting risk acknowledged explicitly. Prior 2026 offerings (Feb–July) raised ~$17.8M via similar structures.

NVE Corporation's Q1 fiscal 2027 (quarter ended June 30, 2026) revenue surged 81% to $11.0M from $6.1M YoY, driven by 82% growth in product sales and 53% growth in contract R&D. Net income jumped 79% to $6.39M ($1.32 diluted EPS) from $3.58M ($0.74 EPS). The company announced a quarterly cash dividend of $1.00 per share payable August 31, 2026. Balance sheet shows strong liquidity: $2.9M cash, $41.0M in marketable securities, and minimal debt.

Phaos Technology Holdings (Cayman) Limited, a pre-revenue or minimal-revenue company with ~$982K in assets, entered into an underwriting agreement with Network 1 Financial Securities, Inc. The agreement contemplates a public offering of Class A ordinary shares and warrants with specific terms left blank (share counts, pricing, and proceeds amounts are not filled in). Network 1 receives a 6.5% underwriting discount, 7.5% representative warrants (exercisable at 125% of public offering price, 5-year term, 180-day lockup), a 0.5% non-accountable expense allowance on gross proceeds, a 7.5% solicitation fee on warrant exercises, and capped out-of-pocket expenses of $75,000–$100,000. The company also granted a 12-month right of first refusal for future financings and a 12-month tail financing fee (6.5% of deal value) on investors introduced by the underwriter.

Crown Castle completed the sale of its Fiber and Small Cell businesses to EQT and Zayo on May 1, 2026, for $8.4 billion in net proceeds ($8.5 billion gross less $124 million adjustments). The company used proceeds to repurchase $1 billion in stock and repay $7 billion in debt. Q2 2026 AFFO increased 10% to $488 million ($1.13/share) vs. Q2 2025; full-year 2026 AFFO guidance raised by $5 million to $1,950–$2,000 million midpoint ($4.53–$4.65/share).

Progress Software (buyer) is acquiring substantially all assets and business of Domo, Inc. (seller) via asset purchase agreement dated July 22, 2026. The agreement transfers Domo's business operations, intellectual property, customer contracts, and certain subsidiaries to Progress; Domo retains specified excluded assets and liabilities. Purchase price structure involves closing cash payment adjusted for working capital and indebtedness; exact dollar amount not disclosed in this exhibit. Transaction requires Domo majority shareholder approval via written consent and is subject to customary closing conditions including regulatory approvals.

On May 21, 2026, Equity Residential (EQR) and AvalonBay Communities announced a definitive all-stock merger of equals creating a combined company with ~$53B equity market cap, ~$71B enterprise value, and 180,000+ rental apartments. For Q2 2026, EQR reported FFO per share of $1.00 (up 2.0% YoY) and Normalized FFO of $1.02 (up 3.0% YoY), with same-store revenues up 1.9% and NOI up 1.4%. The company raised midpoint guidance for 2026 same-store revenue growth to 2.1–2.7% (from 1.2–3.2%) and NOI growth to 1.5–2.1% (from 0.5–2.5%), but withdrew EPS and FFO guidance due to merger pendency. Special shareholder vote is scheduled for August 12, 2026.

NovaGold Resources Inc. agreed to merge with Delaware corporation NovaGold Corporation (controlled by existing NovaGold shareholders) in an arrangement where each NovaGold share converts 1:1 to new voting shares. Simultaneously, Paulson Advisers LLC contributes its 40% interest in Donlin Gold LLC (via Donlin Holdings entities) to the merged company in exchange for new shares at a 10% discount to implied equity value based on July 21, 2026 volume-weighted average price. Deal dated July 21, 2026; Outside Date March 31, 2027; requires court approval, shareholder vote (66.67%), and stock exchange listings.

BridgeBio announced FDA acceptance of its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1), with a PDUFA target action date of May 8, 2027. The Phase 3 CALIBRATE trial met all pre-specified primary and key secondary efficacy endpoints, demonstrating normalization of calcium and PTH markers without need for supplements. The company is also enrolling a pediatric trial (CALIBRATE-PEDS) and plans to initiate RECLAIM-HP Phase 3 in chronic hypoparathyroidism, with an EU regulatory filing planned for H2 2026.

Kaiser Aluminum reported Q2 2026 net sales of $1.3B (up 53% YoY), net income of $97M ($5.72 diluted EPS), and adjusted EBITDA of $166M with 38.1% margin. Conversion revenue reached $437M (up 17% YoY). Management raised FY2026 guidance: Conversion Revenue to high end of 10-15% growth range and Adjusted EBITDA to 45-55% growth (from prior guidance), citing strong packaging demand, improving aerospace, and favorable pricing. Net debt leverage improved to 2.1x from 3.4x at year-end 2025; quarterly dividend increased to $0.77/share.

Adeptus Partners, LLC consented to audit reference in the S-1/A filing dated July 22, 2026. The auditor's report on FY 2025 and 2024 financials contains an explanatory paragraph regarding Starfighters Space's ability to continue as a going concern—a standard but critical disclosure indicating substantial doubt about the company's ability to meet obligations.

Digital Brands Group announced a 1-for-40 reverse stock split effective July 24, 2026, reducing outstanding shares from ~23 million to ~575,000 shares. The split aims to boost stock price above $1.00 per share to meet Nasdaq Listing Rule 5550(a)(2) minimum bid requirements. Authorized shares reduced from 1 billion to 25 million; no shareholder action required.

On July 17, 2026, Datavault AI Inc. (the Guarantor) entered into a Guaranteed Bridge Loan Agreement with ABRI Capital Ltd. (Lender) and NYIAX, Inc. (Borrower). Datavault unconditionally guarantees NYIAX's $833,333 bridge facility at 13% interest plus 10% original issue discount, due September 11, 2026, or immediately upon the NYIAX merger closing (expected July 24, 2026) or Datavault raising $10M+. This is a first-call, on-demand guarantee with broad waivers of surety defenses, making Datavault directly liable for all obligations if NYIAX defaults.

AmpliTech completed its Series A Rights Offering on July 18, 2026, receiving approximately $21.9 million in subscriptions and issuing ~4,384,163 shares of common stock at $6 per share (actual price: $5 inferred from subscription total). The company states it now has record cash and no material debt, planning to deploy capital toward AI-RAN/Open RAN commercialization, working capital, and potential share repurchases. A Series B rights offering ($6 strike) remains open through November 20, 2026. Dealer manager: Moody Capital Solutions.

C3is Inc., a small shipping company with ~$98.5M in assets owning 5 drybulk and tanker vessels, filed an F-1 for a firm-commitment offering of 3,592,814 units (each unit = 1 common share + 1 Class F Warrant) at $1.67/unit, dated July 22, 2026. Net proceeds ~$5.2M ($6.1M with over-allotment). The Class F Warrants feature exercise-price resets to 70% and 50% of initial price on days 2 and 5 post-closing, plus a zero-cash exercise option allowing 2× the shares for no cash. If all warrants exercised zero-cash, up to 16.5M shares could issue without additional cash inflow—severe dilution relative to current 1.55M shares outstanding.

Resources Connection reported fiscal year 2026 revenue of $452.0M (down 18.0% from $551.3M in FY2025) with net loss of $40.6M. Adjusted EBITDA declined sharply to $5.0M (1.1% margin) from $23.5M (4.3% margin) prior year. Key headwinds: 17.5% decrease in billable hours, softer demand in on-demand talent segment due to AI/automation adoption, longer sales cycles in consulting, and executive leadership changes (separation of former CEO and COO with $12.2M in severance/equity costs). Company sold crisis communication subsidiary Sitrick in May 2026 for $2.4M loss. Credit facility covenant violation led to facility termination July 13, 2026; replaced July 15 with $30M secured revolving line tied to receivables.

Public Storage closed its acquisition of National Storage Affiliates Trust (NSA) on July 22, 2026, adding 1,000+ properties and 550,000 units. As part of the deal, PSA OP issued three new series of preferred partnership units: 10,229,928 Series T units, 923,674 Series T-1 units, and 5,668,128 Series U units—all with 6.0% cumulative distributions at $25 stated value per unit, commencing July 1, 2026. NSA shareholders received 0.14 PSA common shares per NSA share. A joint venture of 313 NSA properties (80% owned by legacy NSA LPs, 20% by PSA) was also formed.

XCF Global completed three major financing transactions in July 2026: (1) sold 6,891,798 warrant shares to GL PART SPV II, LLC for $1M (warrant purchase agreement, 7/17/26); (2) borrowed $750K from Hollywood Horizons, Inc. with 25% OID, 10% interest, 60-day term, secured by collateral and 5M penalty-of-default shares (7/16/26); (3) sold 6,666,667 common shares to Lombard Street Partners for $1M in two tranches (7/20/26). Total gross proceeds ~$2.75M. Company must register warrants and shares; faces 1.5% monthly penalties if registration delayed beyond 60 days.

Bluejay Diagnostics announced completion of enrollment in SYMON-II, a pivotal 750-patient multicenter clinical validation study for its Symphony IL-6 rapid diagnostic test for sepsis mortality risk assessment. The study enrolled ahead of schedule and achieved a 17% 28-day mortality event rate, providing what management describes as a robust clinical dataset. Data cleaning and analysis are underway; results are expected to support a planned FDA 510(k) regulatory submission.

LB Pharmaceuticals accelerated the expected topline results timing for its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia from H2 2027 to H1 2027, citing faster-than-expected enrollment across ~460 patients at 25 U.S. sites. The company will schedule a pre-NDA meeting with the FDA in H2 2027. CEO Heather Turner confirmed cash runway extends to Q2 2029, sufficient to fund multiple clinical readouts including Phase 2 ILLUMINATE-1 (bipolar depression, expected Q1 2028) and Phase 2 adjunctive MDD trial (H1 2029).

Standard Nuclear announced construction substantially complete for SN-TN (Tennessee) and SN-ID (Idaho) facilities, which will add up to 5 metric tons uranium per year (1 MTU each initially) to the company's TRISO nuclear fuel production capacity once fully operational. Both facilities received Preliminary Documented Safety Analyses approval from the U.S. Department of Energy and are expected to begin commissioning and licensing activities in summer 2026. The company also continues joint venture fuel production with Framatome in Washington state.

Goosehead reported Q2 2026 total revenues of $113.4M (+21% YoY), core revenues of $95.6M (+10% YoY), net income of $17.0M (vs. $8.3M prior year), and adjusted EBITDA of $37.9M (+30% YoY). Total written premiums increased 14% to $1.34B; policies in force grew 15% to 2.1M. CEO Mark Miller will retire December 31, 2026; Mark Jones Jr., current President/COO, becomes President/CEO effective January 1, 2027. Full-year 2026 guidance raised to 12-19% organic revenue growth and 12-20% written premium growth.

QuantumScape announced a multi-year solid-state battery partnership with Honda (a Top-10 global automaker) on June 18, 2026, following rigorous technology evaluation. The company updated its Volkswagen PowerCo collaboration with amended milestones focused on automotive cells and technology roadmap. Operationally, the Eagle Line pilot production facility in San Jose is ramping with core tools achieving >90% uptime and sample shipments accelerating; capex guidance was lowered to $27–$37M for full-year 2026. Financially, Q2 2026 showed net loss of $98.2M, Adjusted EBITDA loss of $64.2M (in line with guidance), customer billings of $10.8M, and liquidity of $859.0M as of June 30, 2026.

Magnolia Oil Gas Operating LLC priced $500M of 6.625% senior unsecured notes due 2034, closing expected August 5, 2026. Net proceeds will fund 100% acquisition of WildFire Intermediate Holdings LLC from WildFire Energy I LLC, combined with Class A stock offering (closed July 22, 2026), revolving credit borrowings, and cash on hand. No acquisition purchase price disclosed in this filing.

Banner Corporation reported Q2 2026 net income of $48.9M ($1.43/diluted share), down from $54.7M ($1.60) in Q1 2026. On April 30, 2026, Banner entered a definitive merger agreement to acquire Pacific Financial Corporation (Bank of the Pacific) in an all-stock transaction at an exchange ratio of 0.2633 Banner shares per Pacific Financial share; expected to close Q3 2026. Pacific Financial has ~$1.3B assets, $1.1B deposits, $0.8B loans, and 21 offices. Banner's Q2 showed loan growth of $286M (2% QoQ), net interest margin up 2 basis points to 4.13%, efficiency ratio 62.80% (GAAP), and non-performing assets at 0.36% of assets.

Director RA CAPITAL MANAGEMENT, L.P. (PBLS) bought 245K shares (~$6.9M) on the open market (0.9% of holdings). Open-market insider purchase — historically a bullish signal.

Cal-Maine Foods (market cap ~$4.1B) reported fiscal 2026 net income of $316.7M vs. $1,220.0M prior year (−74%), with sales down 31.7% to $2.91B. Conventional shell egg prices collapsed 50.9% YoY due to industry oversupply, while the company simultaneously announced a $54M investment to expand prepared foods capacity by 30% (effective H1 FY2028), acquired an additional Eggland's Best franchise territory (NE region, expected ~5% specialty egg volume growth annually), and shifted segment reporting to isolate three divisions: Conventional Shell Eggs, Specialty Shell Eggs, and Prepared Foods (which grew from $4.1M to $244.8M sales YoY). Prepared foods now represent 8.4% of fiscal 2026 sales vs. 0.1% prior year; combined specialty + prepared foods reached 44.4% of revenue.